EYE ON CHINA
Abstract
Response Biomedical Corp. expands Chinese distribution agreement for RAMP® cardiovascular products.
Nanocarrier drugs for pancreatic cancer now being produced in China.
Cellular Biomedicine Group acquires Chinese PLA General Hospital's CAR-T immuno-oncology technology and clinical data.
VHS Group kicks off the integration of the EAP Industry in China by acquiring ZO's EAP business.
Hua Medicine achieves positive Phase 1b results in diabetes with 4th-Generation glucokinase activator.
2nd World-China Biosimilars Forum 2015 coming back in March.
World-China Generics Forum will take place in March, 2015.
ACT Genomics raises $8 million in its first private funding round.
TWi Biotechnology selects Medidata's cloud-based platform to advance cutting-edge clinical development.
Crown Bioscience expands partnership with The National Resource Center for Mutant Mice (NRCMM) on developing novel immuno-oncology mouse models.
Potential new breathalyzer for lung cancer screening.
First decoded Neobatrachia genome provides new insight for amphibian evolutionary research.
- distribution agreement
- cardiovascular products
- nanocarrier drugs
- pancreatic cancer
- CAR-T immuno-oncology technology
- clinical data
- integration
- acquire
- diabetes
- glucokinase activator
- biosimilars
- generics
- private funding round
- cloud-based platform
- clinical development
- partnership
- mutant mice
- novel immuno-oncology mouse models
- breathalyzer
- lung cancer
- screening
- decoded
- Neobatrachia genome
- amphibian evoluntionary research
